Risk of second cancers after treatment for Hodgkin's disease

M. A. Tucker, C. N. Coleman, R. S. Cox, A. Varghese, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

We estimated the risk of second cancers among 1507 patients with Hodgkin's disease treated at Stanford University Medical Center since 1968. Eighty-three second cancers occurred more than one year after diagnosis, as compared with 15.9 expected on the basis of rates in the general population (relative risk, 5.2; 95 percent confidence interval, 4.2 to 6.5). The mean (±SE) 15-year actuarial risk of all second cancers was 17.6 ± 3.1 percent, of which 13.2 ± 3.1 percent was due to solid tumors. The risk of leukemia appeared to reach a plateau level of 3.3 ± 0.6 percent at 10 years, whereas non-Hodgkin's lymphoma continued to increase, to 1.6 ± 0.7 percent by the end of the follow-up period. The risk of solid tumors did not vary significantly according to treatment category, with the array of neoplasms resembling that previously observed in populations exposed to radiation and in immunosuppressed groups. The risk of leukemia, although elevated after radiation therapy alone (relative risk, 11; 95 percent confidence interval, 1.2 to 3.8), was much higher after either adjuvant chemotherapy (relative risk, 117; 95 percent confidence interval, 69 to 185) or chemotherapy alone (relative risk, 130; 95 percent confidence interval, 26 to 380). These data suggest that the risk of solid tumors after therapy for Hodgkin's disease continues to increase with time.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalNew England Journal of Medicine
Volume318
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Hodgkin Disease
Confidence Intervals
Therapeutics
Neoplasms
Leukemia
Adjuvant Chemotherapy
Non-Hodgkin's Lymphoma
Population
Radiotherapy
Radiation
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988). Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine, 318(2), 76-81.

Risk of second cancers after treatment for Hodgkin's disease. / Tucker, M. A.; Coleman, C. N.; Cox, R. S.; Varghese, A.; Rosenberg, S. A.

In: New England Journal of Medicine, Vol. 318, No. 2, 1988, p. 76-81.

Research output: Contribution to journalArticle

Tucker, MA, Coleman, CN, Cox, RS, Varghese, A & Rosenberg, SA 1988, 'Risk of second cancers after treatment for Hodgkin's disease', New England Journal of Medicine, vol. 318, no. 2, pp. 76-81.
Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine. 1988;318(2):76-81.
Tucker, M. A. ; Coleman, C. N. ; Cox, R. S. ; Varghese, A. ; Rosenberg, S. A. / Risk of second cancers after treatment for Hodgkin's disease. In: New England Journal of Medicine. 1988 ; Vol. 318, No. 2. pp. 76-81.
@article{47b5c863f00d4e9da2593f6cdd8620f4,
title = "Risk of second cancers after treatment for Hodgkin's disease",
abstract = "We estimated the risk of second cancers among 1507 patients with Hodgkin's disease treated at Stanford University Medical Center since 1968. Eighty-three second cancers occurred more than one year after diagnosis, as compared with 15.9 expected on the basis of rates in the general population (relative risk, 5.2; 95 percent confidence interval, 4.2 to 6.5). The mean (±SE) 15-year actuarial risk of all second cancers was 17.6 ± 3.1 percent, of which 13.2 ± 3.1 percent was due to solid tumors. The risk of leukemia appeared to reach a plateau level of 3.3 ± 0.6 percent at 10 years, whereas non-Hodgkin's lymphoma continued to increase, to 1.6 ± 0.7 percent by the end of the follow-up period. The risk of solid tumors did not vary significantly according to treatment category, with the array of neoplasms resembling that previously observed in populations exposed to radiation and in immunosuppressed groups. The risk of leukemia, although elevated after radiation therapy alone (relative risk, 11; 95 percent confidence interval, 1.2 to 3.8), was much higher after either adjuvant chemotherapy (relative risk, 117; 95 percent confidence interval, 69 to 185) or chemotherapy alone (relative risk, 130; 95 percent confidence interval, 26 to 380). These data suggest that the risk of solid tumors after therapy for Hodgkin's disease continues to increase with time.",
author = "Tucker, {M. A.} and Coleman, {C. N.} and Cox, {R. S.} and A. Varghese and Rosenberg, {S. A.}",
year = "1988",
language = "English (US)",
volume = "318",
pages = "76--81",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "2",

}

TY - JOUR

T1 - Risk of second cancers after treatment for Hodgkin's disease

AU - Tucker, M. A.

AU - Coleman, C. N.

AU - Cox, R. S.

AU - Varghese, A.

AU - Rosenberg, S. A.

PY - 1988

Y1 - 1988

N2 - We estimated the risk of second cancers among 1507 patients with Hodgkin's disease treated at Stanford University Medical Center since 1968. Eighty-three second cancers occurred more than one year after diagnosis, as compared with 15.9 expected on the basis of rates in the general population (relative risk, 5.2; 95 percent confidence interval, 4.2 to 6.5). The mean (±SE) 15-year actuarial risk of all second cancers was 17.6 ± 3.1 percent, of which 13.2 ± 3.1 percent was due to solid tumors. The risk of leukemia appeared to reach a plateau level of 3.3 ± 0.6 percent at 10 years, whereas non-Hodgkin's lymphoma continued to increase, to 1.6 ± 0.7 percent by the end of the follow-up period. The risk of solid tumors did not vary significantly according to treatment category, with the array of neoplasms resembling that previously observed in populations exposed to radiation and in immunosuppressed groups. The risk of leukemia, although elevated after radiation therapy alone (relative risk, 11; 95 percent confidence interval, 1.2 to 3.8), was much higher after either adjuvant chemotherapy (relative risk, 117; 95 percent confidence interval, 69 to 185) or chemotherapy alone (relative risk, 130; 95 percent confidence interval, 26 to 380). These data suggest that the risk of solid tumors after therapy for Hodgkin's disease continues to increase with time.

AB - We estimated the risk of second cancers among 1507 patients with Hodgkin's disease treated at Stanford University Medical Center since 1968. Eighty-three second cancers occurred more than one year after diagnosis, as compared with 15.9 expected on the basis of rates in the general population (relative risk, 5.2; 95 percent confidence interval, 4.2 to 6.5). The mean (±SE) 15-year actuarial risk of all second cancers was 17.6 ± 3.1 percent, of which 13.2 ± 3.1 percent was due to solid tumors. The risk of leukemia appeared to reach a plateau level of 3.3 ± 0.6 percent at 10 years, whereas non-Hodgkin's lymphoma continued to increase, to 1.6 ± 0.7 percent by the end of the follow-up period. The risk of solid tumors did not vary significantly according to treatment category, with the array of neoplasms resembling that previously observed in populations exposed to radiation and in immunosuppressed groups. The risk of leukemia, although elevated after radiation therapy alone (relative risk, 11; 95 percent confidence interval, 1.2 to 3.8), was much higher after either adjuvant chemotherapy (relative risk, 117; 95 percent confidence interval, 69 to 185) or chemotherapy alone (relative risk, 130; 95 percent confidence interval, 26 to 380). These data suggest that the risk of solid tumors after therapy for Hodgkin's disease continues to increase with time.

UR - http://www.scopus.com/inward/record.url?scp=0023835089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023835089&partnerID=8YFLogxK

M3 - Article

C2 - 3336397

AN - SCOPUS:0023835089

VL - 318

SP - 76

EP - 81

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -